Prevention, diagnosis, and treatment of delirium in older adults with COVID-19. Literature review

Sara Gloria Aguilar-Navarro,1,2 José Octavio Duarte-Flores,1 Mary Cruz Granados-Valdés,1 María José Suing-Ortega,1 Alberto José Mimenza-Alvarado1,2

1 Servicio de Geriatría Neurológica, Instituto de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
2 Servicio de Geriatría, Instituto de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Correspondence:
Alberto José Mimenza Alvarado
Servicio de Geriatría Neurológica, Instituto de Ciencias Médicas y Nutrición Salvador Zubirán.
Vasco de Quiroga 15, Belsario Domínguez Secc. 16, 14080, Tlalpan, Ciudad de México, México.
Phone: 55 (54) 166-463, (54) 870-9000, Ext. 5711
Email: a.mimenza@hotmail.com

Received: 24 June 2020
Accepted: 17 August 2020

Citation:
DOI: 10.17711/SM.0185-3325.2020.043

ABSTRACT

Background. COVID-19 affects several systems in the body, including the central nervous system (CNS), expressed in the form of headaches, hyposmia, cerebrovascular disease, and neuropathy. Older Adults (OA) are vulnerable to this infection, and may also present delirium, which may be the result of the virus directly affecting the CNS or of systemic inflammation during infection. Objective. To determine the clinical characteristics, risk factors, pathophysiology, treatment measures, and prevention of delirium associated with COVID-19 from a review of the literature in times of the SARS-CoV-2 pandemic. Method. A search was conducted in PubMed, SciELO, UpToDate, and Medscape using keywords in English and Spanish. Results. Seventy-two articles were reviewed. We analyzed inclusion and exclusion criteria and 43 articles with relevant information for the narrative description of the review were selected. Twenty to thirty per cent of the COVID-19 patients will present or develop delirium, or changes in mental status during their hospitalization, with rates of 60% to 70% in severe illness. The exact mechanisms are likely to be multifactorial. There is a worrying lack of attention to the implications of identifying and managing delirium in the response to this pandemic. Discussion and conclusion. Delirium is a frequent neurological manifestation in OA with COVID-19 and requires early identification, as well as the implementation of non-pharmacological and pharmacological treatment strategies, which may reduce the associated morbidity and mortality in this age group.

Keywords: COVID-19, SARS-CoV-2, delirium, older adult.

RESUMEN

Antecedentes. La COVID-19 afecta múltiples sistemas del organismo. Uno de ellos es el sistema nervioso central (SNC), cuya afección se manifiesta con cefalea, hiposmia, enfermedad vascular cerebral y neuropatía. Además de que los adultos mayores (AM) son vulnerables a esta infección, pueden presentar delirium, el cual puede ser resultado de una afección directa del virus al SNC o resultado de la inflamación sistémica durante la infección. Objetivo. Conocer las características clínicas, factores de riesgo, fisiopatología, medidas de tratamiento y prevención del delirium asociados a COVID-19 a partir de la revisión de la literatura en tiempos de la pandemia por SARS-CoV-2. Método. Se realizó una búsqueda en PubMed, SciELO, UpToDate y Medscape utilizando palabras clave en inglés y español. Resultados. Se revisaron 72 artículos, se analizaron criterios de inclusión y exclusión y se seleccionaron 43 artículos con información relevante para la descripción narrativa de la revisión. El 20-30% de los pacientes con COVID-19 presentarán o desarrollarán delirium, o cambios en su estado mental durante el curso de su hospitalización, con tasas del 60-70% en enfermedad grave. Es probable que los mecanismos exactos sean multifactoriales. Existe una preocupante falta de atención a las implicaciones de la identificación y el manejo del delirium en la respuesta a esta pandemia. Discusión y conclusión. El delirium es una manifestación neurológica frecuente en los AM con COVID-19 y requiere su identificación temprana, así como la implementación de estrategias de tratamiento no farmacológico y farmacológico, lo que puede disminuir la morbilidad asociada en este grupo etario.

Palabras clave: COVID-19, SARS-CoV-2, delirium, adulto mayor.
BACKGROUND

The 2019 novel Coronavirus (COVID-19) pandemic began in Wuhan, China in December 2019 (World Health Organization, 2020). This disease is characterized by producing a severe acute respiratory syndrome, caused by the SARS-CoV-2 virus (RNA virus) (Mao et al., 2020). It has severely affected Europe, the United States and the Americas with Mexico being one of the countries in the continent with the highest number of reported cases, after the US and Brazil. By June 21, 2020, Mexico had reported 5,343 new cases, 180,545 accumulated cases, and 21,825 deaths, 31.2% of which correspond to people over 60 (Gobierno de México, 2020; MMS Consulting, 2020). Although COVID-19 typically affects the respiratory system with varying degrees of severity, some patients may experience damage to other organs and systems (renal, cardiac, or hematological), in addition to the central and peripheral nervous system.

One form of presentation of COVID-19 is delirium, defined as a neuropsychiatric manifestation, characterized by an acute change in attention and cognition, with a fluctuating course. It is a common condition in older adults (OA) with physical or mental illness, which increases morbimortality in addition to being considered a geriatric emergency (Kennedy, Hwang, & Han, 2020). The prevalence of delirium associated with COVID-19 in hospitalized patients is 10% to 15% (LaHue et al., 2020; Rogers et al., 2020), although it can increase to 50% to 70% in Intensive Care Units.

Delirium is a well-known complication of respiratory diseases such as pneumonia in older adults. Early studies indicate that 20% to 30% of patients with COVID-19 will present or develop delirium or changes in mental status during the course of their hospitalization, with rates of 60% to 70% in cases of serious illness at all ages (Helms et al., 2020; Mao et al., 2020). The exact mechanisms of this association are probably multifactorial, including direct neurological invasion, cerebrovascular involvement, and more indirectly, through hypoxia, fever, dehydration, inflammation (pro-inflammatory cytokine storm), medications, and metabolic disturbances. Despite this, there has been a worrying lack of attention to the implications of identifying and managing delirium in the response to this pandemic.

Moreover, the presence of delirium in OA increases healthcare resource use and complication rates associated with hospitalization. The presence of a greater number of risk factors and the modification of services during the pandemic (such as the need for isolation in hospitals) due to COVID-19 probably contributes to increasing the presence of delirium in OA (Helms et al., 2020; LaHue et al., 2020; Lovell et al., 2020). Accordingly, the objective of this review is to determine the clinical characteristics, risk factors, pathophysiology, and treatment and prevention measures for delirium associated with COVID-19.

METHOD

A review of the literature on delirium and COVID-19 was conducted using the following search engines: PubMed, Scielo, UpToDate, and Medscape. The search was limited to human studies and included documents published during the period from December 2019 to June 2020, and publications that included countries affected by COVID-19. The following keywords were used in English and Spanish, with MeSH terms: “COVID-19,” “Delirium,” “Elderly,” “Pathophysiology,” “Treatment,” “Complications,” “Prevention,” “Clinical Guidelines,” and “Clinical Trials” to answer the following research question: What are the clinical characteristics, risk factors, pathophysiology, and delirium treatment and prevention measures associated with COVID-19 in Older Adults?

For the inclusion criteria, articles related to delirium and COVID-19, descriptive, prospective, or retrospective studies, reviews, letters to the editor, as well as related clinical practice guidelines were considered. Only articles in which it was not possible to have full access to the contents, as well as those in a language other than Spanish or English or which did not provide full access to the text, were excluded.

An initial search was conducted, yielding 72 results. Articles were organized according to the inclusion and exclusion criteria, the main ones being review articles in English, clinical practice guidelines, and letters to the editor. Once all the sources had been included, they were organized by topic and lastly 43 articles with relevant information were selected for the narrative description of the review (Figure 1).

Risk factors for COVID-19 disease and aging

The risk in OA of developing delirium is due to the changes inherent in aging, and possibly the greater number of risk factors previously described for delirium (Marcantonio, 2017), although not all OA will necessarily suffer from delirium. One predisposing factor is immunosenescence, characterized by a decrease in the function of the innate, adaptive immune system, which affects the body’s ability to respond to pathogens (Tay, Poh, Renia, MacAry, & Ng, 2020). Immunosenescence triggers a phenomenon called inflammation due to advanced age (inflammaging), which maintains a chronic, low-grade, subclinical inflammatory state, which in turn continuously produces pro-inflammatory cytokines (IL-1) and Tumor Necrosis Factor alpha (TNF alpha), as well as a decrease in immunomodulatory cytokines (IL-2). This low-grade inflammation is called the senescence-associated secretory phenotype (SASP). These physiological changes could explain the greater severity of COVID-19 in OA. At the same time, there are also molecular changes in the Central Nervous System (CNS), such
Delirium in older adults with COVID-19

as, for example, the deterioration of mitochondrial function, oxidative stress, changes in energy metabolism, and alteration in the synthesis of neurotransmitters, which make OA more vulnerable to presenting delirium (Di Benedetto, Müller, Wenger, Düzel, & Pawelec, 2017).

Physiopathological mechanisms of COVID-19 on the Central Nervous System

Neurological symptoms have been described in severe forms of COVID-19 or severe COVID-19 more often than in those with mild symptoms (Kotfis et al., 2020). In a series of 214 patients with COVID-19, Mao et al. (2020) demonstrated that 36.4% developed neurological symptoms (such as headaches, impaired consciousness, or paresthesias). In turn, Xiang et al. (2020) reported the first case of SARS-CoV-2 viral encephalitis in China, showing, through the analysis of cerebrospinal fluid and genome sequencing, the ability of this virus to damage the nervous system. Initially, knowledge of the neurotropism of SARS-CoV-2 could be explained by the genetic similarity (79.5%) with SARS-CoV (Wu et al., 2020a). Current evidence shows that some COVID-19 patients have symptoms like those of an intracranial infection (headaches, epilepsy, and disturbances of consciousness) (Wu et al., 2020b). At the same time, there is evidence that some patients have symptoms related to COVID-19 after neurological manifestations such as hypoesthesia or hyposmia, (Mao et al., 2020; Mimenza-Alvarado, Avila-Funes, & Aguilar-Navarro, 2020).

Toxic infectious encephalopathy (TIE), also known as acute toxic encephalitis, is a syndrome of reversible brain dysfunction caused by the presence of systemic toxemia, metabolic disorders, and hypoxia during the acute infection process. It is important to mention that this encephalopathy was initially described in patients with influenza or severe sepsis (Mizuguchi, Yamanouchi, Ichiyama, & Shiomi, 2007; Tauber, Effert, Brück, & Nau, 2017). From a pathological point of view, it is related to the presence of cerebral edema without evidence of inflammation in the cerebrospinal fluid (CSF). Clinically, patients may present headaches, dysphoria, and delirium, although in some cases there may be loss of consciousness and coma. As mentioned earlier, patients with COVID-19 can present neurological symptoms in up to 50% of cases. Autopsy studies of patients who suffered from this disease have confirmed the presence of cerebral edema. Accordingly, COVID-19 is likely to produce a TIE, although more studies are required to confirm this theory (Xu et al., 2020).

Coronaviruses (CoVs) can directly affect the nervous system since the presence of genetic material and certain proteins in the nervous system has been demonstrated. Other pathways related to the involvement of the nervous system are through blood circulation (little evidence for SARS-CoV-2), neuronal, hypoxia (associated with cerebral edema, intracranial hypertension, among others) (Abdenour, Zeghal, Dème, & Puybasset, 2012; Mao et al., 2020). As mentioned earlier, alterations in the cellular immune system may also explain the damage to the nervous system, since neurotropic viruses activate glial cells to induce a pro-inflammatory state through the release of interleukins (IL), mainly IL-6 (related to the pro-inflammatory cytokine storm) that occurs in severe COVID-19 (Wan et al., 2020). The relationship between the changes described and inflammation due to advanced age (inflammaging) (also associated with the release of IL-6) probably explains the presence of delirium in this age group. In addition, plasma levels of other pro-inflammatory cytokines (IL-8, IL-10, IL-2) are higher in patients with severe COVID-19 (Troyer, Kohn, & Hong, 2020).

Finally, the presence of angiotensin-converting enzyme 2 (ACE2) in the CNS is related to damage to the blood-brain barrier (BBB), which could facilitate the penetration of the virus into the CNS through the vascular system (Baig, Khaleeq, Ali, & Syeda, 2020).

Clinical characteristics and diagnosis of delirium in COVID-19

The presence of delirium could also be an early symptom of COVID-19, which is why, in all OA patients, any respiro-
tory or gastrointestinal symptoms that suggest this disease should be investigated (Alkeridy et al., 2020). The current recommendation in OA care in times of the SARS-CoV-2 virus pandemic is early detection of delirium (Figure 2).

In the absence of a specific scale for the diagnosis of delirium in a patient with COVID-19 it is recommended to use the Confusion Assessment Method (CAM) (figure 3), which is the most widely used tool, it is brief, and does not require prior training, in addition to having 46%-94% sensitivity and 63%-100% specificity in the context of delirium due to any cause (British Geriatrics Society, European Delirium Association, & Old Age Psychiatry Faculty, 2020; Davis, Searle, & Tsui, 2019; Herling et al., 2018).

Delirium is characterized by its fluctuating condition, so it is advisable to question the family and/or caregiver regarding the previous mental state, since there could be a history of dementia, vascular lesions, or even a previous history of delirium. It is advisable to consider, once the diagnosis of SARS-CoV-2 infection has been ruled out (or confirmed), complementary studies to rule out or confirm other conditions that could also contribute to delirium and, depending on the clinical context, run further studies that will make it possible to document a direct disorder of the CNS (cerebral vascular event, encephalitis, thrombosis, among other causes) with neuroimaging studies or the analysis of the CSF (Marcantonio, 2017). Once SARS-CoV-2 infection has been ruled out, any direct CNS disorder (discussed above) or any hydroelectrolytic disorder, infection of another system or organ, recent use or adjustment of drugs, metabolic decontrol, presence of pain, or any other pathology that could explain delirium should also be discounted (Ford, 2016).

Interventions in delirium and COVID-19

Non-pharmacological interventions

Although delirium associated with COVID-19 in OA might appear to be an unavoidable condition, by using preventive measures it is possible to reduce its emergence in 30% to 40% of cases. Standardized protocols have been shown to improve the quality of care in hospitalized patients (by preventing functional and cognitive deterioration), such as the Hospital Elder Life Program (HELP), which includes an intervention program in the areas of mobility, sensory and auditory alterations, orientation, nutrition, hydration, and the sleep-wake cycle. This program has been successfully implemented in over 30 hospitals worldwide (Ferrarese et al., 2020). At the same time, OA who are being treated at ICUs (Intensive Care Units), where delirium prevention and care measures have also been shown to have a great impact, should be considered. One of the recommended models is the one proposed by the Society of Critical Care Medicine (SCCM), which includes management of analgesia, sedation, and delirium care (Barr & Pandharipande, 2013). Through the ICU Liberation initiative, Wesley Ely’s group promotes the protocol that includes the following: (Assess): pain prevention and management measures, (Both): evaluation of the state of consciousness, breathing and analgesia-sedation, (Choice): evaluate and prevent Delirium, (Early): mobility and early exercise, (Family): commitment and accompaniment, known as the ABCDEF of delirium (As-
Delirium in older adults with COVID-19

Delirium prevention programs are essential in the era of COVID-19 and should not be omitted, despite the challenges related to the measures established in hospitals, such as, for example, the prohibition of visits to patients, the need to use face masks as well as personal protective equipment (PPE). Since their intervention could reduce isolation, favor daytime stimulation, regulate the sleep-wake cycle, and monitor the individual needs of the patient a key aspect is the role played by health personnel in delirium prevention (Park & Lee, 2019). For this reason, current recommendations consider the support of a caregiver/family member accompanying the OA during COVID-19 care, always using PPE, and attending for short periods (LaHue et al., 2020). Figure 4 shows some strategies adapted to the Mexican environment, with an emphasis on the evaluation and prevention of delirium in patients hospitalized in acute care wards and/or who are discharged from ICU.

Pharmacological treatment

Current recommendations state that drug treatment should only be started in patients with delirium who present agitation, aggression, paranoia, hallucinations, and/or when, in addition, these symptoms pose a risk of imminent harm to the patient or their caregiver (Meagher et al., 2020). For the choice of the antipsychotic agent, the desired clinical effect, pharmacokinetic, and pharmacodynamic profile, as well as

---

**Figure 4.** Delirium management algorithm of the Salvador Zubirán National Institute of Medical Sciences and Nutrition Geriatrics service. CNS, Central Nervous System; CAM, Confusion Assessment Method; ICU, Intensive Care Unit; CVE, Cerebral Vascular Event; PT, Pulmonary Thromboembolism; SC, Subcutaneous; IM, Intramuscular; IV, Intravenous; VO, Via Oral; mg, milligrams.
its safety (adverse effects), should be considered (Ostuzzi et al., 2020). The characteristics of the antipsychotics used in the treatment of delirium in general, as well as some considerations in the treatment for COVID-19 and their potential risk of interactions with the antipsychotic, are shown in Table 1.

In its clinical practice guide for the treatment of delirium and COVID-19, The British Geriatrics Society (BGS) recommends screening for delirium in risk groups (pre-existing cognitive impairment, depression, men, sensory deprivation) and regular evaluation of their mental state, in addition to ruling out any other possible precipitating factor. For cases in which rapid control of symptoms is required, such as agitation, the first-line recommendation is haloperidol (maximum dose 5 mg in 24 hours) (di Giacomo et al., 2020). However, it should be recalled that in OA with Parkinson’s disease or Lewy body dementia, the use of this drug could exacerbate extrapyramidal symptoms (Ward & Citrome, 2018).

At the same time, patients with perceptual and circadian cycle disorders may benefit from the use of sedative antipsychotics, such as quetiapine (Atkin, Comai, & Gobbi, 2018). Regarding dosage, antipsychotics should be started at low doses on a daytime basis, as needed and according to the severity of the patient’s symptoms. Conversely, if frequent doses are required, they should be gradually increased and modified according to the clinical evolution of the patient, reserving the daytime dose for use as required (Rieck, Pagali, & Miller, 2020). Benzodiazepines are generally considered a poor option for delirium treatment. However, it has been observed that in patients with COVID-19 and severe agitation, the use of lorazepam in combination with antipsychotic agents could allow greater sedation, although patient vigilance should be extreme due to the risk of presenting respiratory depression in patients with pneumonia (Ostuzzi et al., 2020). It is important to note that to date, according to the evidence, prophylactic use of antipsychotics is not recommended in the context of delirium associated with COVID-19 (Fimucane et al., 2020).

Since antipsychotics may have interactions related to QTc prolongation with certain drugs commonly used in COVID-19 (azithromycin), with a greater risk with the use of typical antipsychotics, the risk of interaction can be reduced when using atypical antipsychotics such as risperidone or olanzapine (Frontera et al., 2020).

At the same time, special care should be taken with the use of antipsychotics and opiates, since morphine, for example, plus risperidone require monitoring the respiratory rate and blood pressure, so it is recommended to reduce the dose of either of the two and use the minimum effective dose of both and for the shortest possible time, to avoid the risk of respiratory depression and/or arterial hypotension (due to the additive effect). This recommendation also applies to haloperidol. In the case of morphine and quetiapine, the presence of constipation/paralytic ileus or any other anticholinergic effect should be monitored (Ostuzzi et al., 2020).

The combination of morphine and hydroxychloroquine sulfate may increase the risk of seizures (due to the additive effect). There is no known interaction between chloroquine and morphine, or between the latter and tocilizumab (University of Liverpool, 2020).

**DISCUSSION AND CONCLUSION**

The studies included in this review show that patients with COVID-19 presented neurological manifestations that include the central and peripheral nervous system, since it causes hypoguesia, anosmia, cerebrovascular disease, headache, altered state of consciousness, and neuropsychopathy (Menza-Alvarado et al., 2020). It is considered that delirium could be an early manifestation in OA with this disease, so it is important to identify it routinely, since inadequate or delayed diagnosis is associated with greater morbidity and mortality (Rieck et al., 2020).

The pathophysiology of delirium in COVID-19 is related to a direct mechanism through the involvement of the virus in the CNS, causing toxic infectious encephalopathy, or caused by hematogenous dissemination, as well as indirect effects (systemic and cerebral hypoxia) and inflammatory alterations, among others. These changes, together with the low-grade inflammation that accompanies aging, could be elements that encourage the presentation of severe forms of COVID-19 in OA, also associated with comorbidity and risk factors (Tay et al., 2020).

Regarding its treatment, recent studies have documented the lack of efficacy and the potential for adverse events related to the use of antipsychotics to treat delirium associated with COVID-19 (Nikooie et al., 2019). While non-pharmacological approaches are effective and the mainstay of delirium treatment, aspects such as reorientation, maintaining communication, early mobilization, relaxation exercises, and maintaining the sleep-wake cycle could be more difficult to implement in times of COVID-19. Nevertheless, these measures should be a priority for its management (Blanco Artola, Gómez Solórzano, & Arce Chaves, 2020).

At the same time, implementation of delirium prevention measures is essential, particularly in patients with hospital management for COVID-19, since isolation, restrictions on family visits, limited physical contact with health personnel, and the use of PPE can depersonalize and impress OA, particularly those with underlying dementia or cognitive impairment (LaHue et al., 2020). The current approach has resulted in intense social isolation, as well as increased use of physical and pharmacological restraints for anxiety and agitation management, which can increase the risk of developing delirium, exacerbate and prolong the
### Table 1

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability (oral, IV)</th>
<th>Dosage (oral, IV)</th>
<th>Interaction with LOP/r</th>
<th>Interaction with HCQ</th>
<th>QTC Increase</th>
<th>QTc Increase</th>
<th>Dose Increase</th>
<th>QTc Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Delirium</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>125 mg, oral, IV</td>
<td>250-500 mg/day</td>
<td>Increase in QTc</td>
<td>Increase in QTc</td>
<td>Moderate</td>
<td>No interaction</td>
<td>No interaction</td>
<td>None</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>0.25-1 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quetiapine</td>
<td>25-100 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zolpidem</td>
<td>5-10 mg/day</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Zopiclone</td>
<td>7.5-15 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Loxapine</td>
<td>25 mg/day IV</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>1-4 mg/day</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Clozapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Amantadine</td>
<td>200-300 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>10-60 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Risperidone</td>
<td>1.25-3.50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paliperidone</td>
<td>3-9 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>20 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Risperidone</td>
<td>1.25-3.50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paliperidone</td>
<td>3-9 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>20 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Risperidone</td>
<td>1.25-3.50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>20 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Risperidone</td>
<td>1.25-3.50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>20 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Risperidone</td>
<td>1.25-3.50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>12.5-50 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>20 mg/day oral</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>2-15 mg/day in capsule</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
duración del proceso, y acelerar la mortalidad. Mientras que no es posible el establecimiento de un objetivo comparativo entre los resultados. No obstante, el propósito de esta revisión se basa en el hecho de que las recomendaciones para el control de delirio en pacientes con COVID-19 son similares a las recomendaciones generales para el control de delirio en personas mayores. Además de la presentación de delirio como una amenaza temprana, la manifestación de la enfermedad del sistema nervioso central puede ser más severa en aquellos con COVID-19, lo que podría acelerar la detección de delirio durante la pandemia.

Como resultado de los cambios dinámicos en el conocimiento relacionados con la pandemia del COVID-19 y el constante cambio en las guías de tratamiento, las recomendaciones emitidas en esta revisión son limitadas, y la mayoría de los estudios incluidos fueron descriptivos en naturaleza, con una variedad de metodología. En consecuencia, no es posible establecer un objetivo comparativo entre los resultados. Sin embargo, el alcance de esta revisión se basa en la factibilidad de las recomendaciones para el control de delirio en pacientes con COVID-19 a lo que las recomendaciones de tratamiento de delirio en personas mayores tienen un impacto en la reducción de la morbilidad y la mortalidad.

Abarca mayores adultos con COVID-19 son susceptibles a la presentación de delirio como un acontecimiento temprano, la manifestación de la enfermedad, o como una complicación de la misma, es necesario implementar medidas preventivas, además de la administración farmacológica y el tratamiento farmacológico para aquellos que sufren de ella. Las recomendaciones para el control de delirio en pacientes con COVID-19 no se realizan sin incluir un análisis de riesgo del delirio, lo que podría ser el resultado de una detección temprana del delirio durante la pandemia de COVID-19 en particular en personas mayores.
Delirium in older adults with COVID-19


